iTeos Therapeutics (NASDAQ:ITOS) Stock Rating Reaffirmed by Wedbush

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research report issued on Thursday, RTT News reports. They currently have a $21.00 price objective on the stock. Wedbush’s target price would suggest a potential upside of 42.76% from the company’s current price.

Separately, HC Wainwright increased their price objective on shares of iTeos Therapeutics from $44.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, May 13th.

iTeos Therapeutics Stock Down 1.8 %

Shares of iTeos Therapeutics stock traded down $0.26 during trading on Thursday, hitting $14.71. 261,589 shares of the company were exchanged, compared to its average volume of 347,005. The firm has a 50 day moving average price of $15.91 and a 200 day moving average price of $13.53. The stock has a market capitalization of $531.37 million, a price-to-earnings ratio of -3.89 and a beta of 1.40. iTeos Therapeutics has a fifty-two week low of $8.20 and a fifty-two week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Friday, May 10th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.05). Analysts predict that iTeos Therapeutics will post -4.57 earnings per share for the current year.

Institutional Trading of iTeos Therapeutics

A number of large investors have recently modified their holdings of ITOS. Federated Hermes Inc. boosted its holdings in shares of iTeos Therapeutics by 4,648.4% in the fourth quarter. Federated Hermes Inc. now owns 2,944 shares of the company’s stock worth $32,000 after buying an additional 2,882 shares during the period. Gladius Capital Management LP boosted its position in shares of iTeos Therapeutics by 48.7% in the fourth quarter. Gladius Capital Management LP now owns 3,131 shares of the company’s stock worth $34,000 after buying an additional 1,026 shares during the period. Signaturefd LLC grew its holdings in shares of iTeos Therapeutics by 268.5% during the fourth quarter. Signaturefd LLC now owns 4,481 shares of the company’s stock valued at $49,000 after buying an additional 3,265 shares in the last quarter. AJOVista LLC acquired a new position in iTeos Therapeutics during the fourth quarter valued at $57,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in iTeos Therapeutics by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,877 shares of the company’s stock worth $94,000 after acquiring an additional 2,737 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.